Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4DMedicalFDMDF 53 Cash-to-Debt is 5.54 as of Dec. 2025, which is 32% below its 10-year median of 8.19. GuruFocus rates FDMDF with a GF Score™ of 53/100 and a GF Value™ of $0.89 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, 4DMedical ranks better than 67.61% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 4DMedical's cash to debt ratio for the quarter that ended in Dec. 2025 was 5.54.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 4DMedicalcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for 4DMedical's Cash-to-Debt or its related term are showing as below:
FDMDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47 Med: 8.19 Max: 55.18
Current: 5.54
During the past 6 years, 4DMedical's highest Cash to Debt Ratio was 55.18. The lowest was 0.47. And the median was 8.19.
FDMDF's Cash-to-Debt is ranked better than 67.61% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs FDMDF: 5.54
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
4DMedical Cash-to-Debt Related Terms
4DMedical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for 4DMedical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, 4DMedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4DMedical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where 4DMedical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4DMedical (FDMDF) has a Cash-to-Debt of 5.54 as of Dec. 2025. This is 32% below median its historical median of 8.19. Over the past decade, 4DMedical's Cash-to-Debt has ranged from 0.47 to 55.18. According to the industry distribution chart, 4DMedical ranks #263 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 32.4%.
Is 4DMedical's Cash-to-Debt too high?
4DMedical's current Cash-to-Debt of 5.54 is 32% below median its 10-year median of 8.19. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 55.18. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. 4DMedical's value of 5.54 is 229.8% above this industry median. Based on the distribution chart, 4DMedical ranks #263 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, 4DMedical has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 4DMedical ranks #263 out of 812 companies for Cash-to-Debt. This puts 4DMedical in the upper half of its industry. The industry median Cash-to-Debt is 1.68. 4DMedical's value of 5.54 is 229.8% above this benchmark. Historically, 4DMedical's own Cash-to-Debt has ranged from 0.47 to 55.18 over the past decade. While the company's 10-year median is 8.19 vs. the industry median of 1.68, 4DMedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4DMedical's current Cash-to-Debt of 5.54 is 229.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4DMedical's current Cash-to-Debt is 5.54, which is 32% below median its own 10-year median of 8.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (FDMDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.89, compared to a current price of $2.95 — trading 231.5% above its estimated fair value. The current Cash-to-Debt is 5.54, which is 32% below median its 10-year median of 8.19 and 229.8% above the Medical Devices & Instruments industry median of 1.68. 4DMedical's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For 4DMedical (FDMDF), the current Cash-to-Debt is 5.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4DMedical (FDMDF) Overvalued in 2026?
Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued.
The current stock price of $2.95 is trading 231.5% above its estimated GF Value™ of $0.89.
GuruFocus considers 4DMedical to be Significantly Overvalued.
Key valuation signals for FDMDF:
Cash-to-Debt: 5.54 (32% below median its 10-year median of 8.19)
GF Value™: $0.89 vs. price of $2.95 (231.5% above fair value)
Industry Position: 229.8% above the Medical Devices & Instruments median (#263 of 812)
No single metric tells the full story. See the FDMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
53GF Score
Get the complete analysis for FDMDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMDF has been successfully added to your 
